Patients with uncontrolled asthma had reduced symptoms and exacerbations with tezepelumab, according to a new study.
Tezepelumab was effective in improving forced expiratory volume per 1 second (FEV1), reducing disease symptom score, and decreasing risk of exacerbations among patients with uncontrolled asthma. However, the risk of adverse events suggests careful monitoring and management when using tezepelumab to treat patients with asthma.
“Cumulative evidence has focused on the safety and tolerability of tezepelumab in asthma patients by evaluating a wide range of data, including clinical trials and post hoc analyses of clinical trials,” wrote the researchers of the study. “Tezepelumab had a good efficacy and safety profile in the previous study. However, there remains a significant need for more extensive data to guide future research and clinical use.”
The full systemic review and metanalysis study is published in Medicine (Baltimore).
In the study, the researchers aimed to measure the efficacy and safety after treatment with tezepelumab compared with placebo. Efficacy was evaluated using severe asthma exacerbation rate, FEV1, and an asthma control questionnaire score of 6 (ACQ-6). In terms of safety, the researchers noted serious and nonserious adverse events, including adverse events that led to treatment discontinuation.
Databases PubMed, Embase, Cochrane Central Trials, and Web of Science were searched from inception to April 1, 2022.
Inclusion criteria for the analysis were full text articles, studies on patients with uncontrolled asthma, randomized control trials, studies using tezepelumab as the intervention, studies comparing tezepelumab to a placebo or comparators, and studies that reported clinical efficacy and safety as the outcome.
A total of 1033 articles were found from the database; 383 were excluded for being duplicates, 643 were ineligible, and 3 articles were excluded after review. After exclusion, 4 studies with 1600 patients were eligible for the meta analysis.
The pooled analysis showed a significant decrease in annual asthma exacerbations, (odds ratio [OR], 0.67; 95% CI, 0.57 to -0.80; P < .00001), and a difference in the mean (SD) ACQ-6 scores between patients treated with tezepelumab compared with the placebo (SD, –0.29; 95% CI, –0.39 to –0.20; P < .00001). Furthermore, tezepelumab was found to significantly improve FEV1 (SD, 0.28; 95% CI, 0.11-0.45; P = .001).
The pooling estimates no significant difference in adverse events that led to discontinuation of treatment between the tezepelumab group and the placebo group (OR, 0.66; 95% CI, 0.34-1.26; I2 = 0%) or other nonserious adverse events (OR, 0.89; 95% CI,0.73-1.09; I2 = 58%) compared with the placebo. However, pooling analysis showed patients in the tezepelumab group experienced a significant decrease in the incidence of serious (OR, 0.66; 95% CI, 0.49-0.90; I2 = 0%) or any adverse events (OR, 0.78; 95% CI, 0.62-0.99; I2 = 0%) compared with the placebo. Furthermore, tezepelumab was associated with including nasopharyngitis, headache, and bronchitis after patients received asthma treatment.
The researchers acknowledged some limitations to the study, including it being a small retrospective study with only 1 placebo.
Despite limitations, the researchers believe the study shows the efficacy of tezepelumab in treating patients with uncontrolled asthma. However, the study also showed that tezepelumab was associated with some adverse events compared with placebo, and it called for careful management of adverse events if tezepelumab is used to treat patients with asthma.
“Regarding safety, tezepelumab was associated with a lower risk of adverse events, especially nasopharyngitis, headaches, and bronchitis, compared to placebo,” wrote the researchers. “The use of tezepelumab in the treatment of asthma patients had a higher prevalence of asthma and upper tract infection, which suggested that careful management of these adverse events is required.”
Reference
Lin F, Yu B, Deng B, He R. The efficacy and safety of tezepelumab in the treatment of uncontrolled asthma: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2023;102(32):e34746. doi:10.1097/MD.0000000000034746
A new federal rule will enable thousands of immigrants in the Deferred Action for Childhood Arrivals (DACA) program to obtain health care through the Affordable Care Act; a forthcoming CMS rule is expected to lower home-based care wait times and raise caregiver wages; the HHS Office for Civil Rights has finalized 2 rules that strengthen the ACA’s health care discrimination ban.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Initiating BP Medication Linked to Higher Fall, Fracture Risks in Nursing Home Residents
May 2nd 2024Among over 60,000 nursing home residents who initiated antihypertensive medication, rates of excess fractures due to falls per 100 person-years were as high as 5 among certain patient groups, such as those with dementia and high blood pressure (BP).
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More